Corgenix Appoints Veteran Pharmaceutical Executive to Board Of Directors; New Addition to Board Brings Wealth of Experience Building Companies and Sales Organizations within the Healthcare Industry.

DENVER -- Corgenix Medical Corporation (OTC BB: CONX), a worldwide marketer of diagnostic test kits, adds significant depth of experience to its Board by naming Robert Tutag a director of the Company. Mr. Tutag has served since 1990 as the President of Unisource, Inc., a privately held Boulder, Colorado, company that identifies and develops niche pharmaceutical products for generic and brand name pharmaceutical companies.

"We at Corgenix are thrilled to announce the addition of Robert Tutag to our Board of Directors," commented Douglass T. Simpson, President and CEO of Corgenix. "We are confident that Robert's extensive experience building sales forces and companies in the healthcare industry will prove to be a tremendous asset to Corgenix as we move forward in the development and marketing of our novel diagnostic products."

Prior to joining Unisource, Mr. Tutag was President and Chief Executive Officer of Tutag Corporation. In this role, which he fulfilled for 18 years, he developed and managed operations of Cord Laboratories, one of the nation's premier generic pharmaceutical manufacturing companies, in addition to founding Geneva Generics, a generic sales and distribution company. Both Cord Laboratories and Geneva Generics were acquired by Ciby-Geigy Corporation. During his time with Tutag Corporation, Mr. Tutag also served as Vice President of Sales and a Director of Tutag Pharmaceuticals, a branded distribution company.

Past experience also includes work in the banking industry, including a position as President and Chief Executive Officer of NBR Financial, Inc., a multi-bank holding company. Additionally, Mr. Tutag has served as editor of GMP Trends, Inc. since 1977, an informational newsletter that reviews FDA and GMP inspection reports for the pharmaceutical and medical device industries. Mr. Tutag received his BBA and MBA from the University of Michigan.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at www.corgenix.com.